Arg237
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Mono-methylation Site Page: > Arg237  -  PSF (mouse)

Site Information
GGEPrGGrQHHAPYH   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 6009321

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 )
Disease tissue studied:
testicular cancer ( 18 )
Relevant cell line - cell type - tissue:
'brain, embryonic' ( 27 ) , brain ( 1 , 2 , 3 , 4 , 26 ) , embryo ( 1 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 ) , MEF (fibroblast) ( 19 , 20 , 21 , 22 ) , P19 (testicular) ( 18 )

References 

1

Guo A, et al. (2014) Immunoaffinity enrichment and mass spectrometry analysis of protein methylation. Mol Cell Proteomics 13, 372-87
24129315   Curated Info

2

Guo A (2013) CST Curation Set: 18334; Year: ; Biosample/Treatment: tissue, brain/-; Disease: -; SILAC: -;
Curated Info

3

Guo A (2013) CST Curation Set: 18335; Year: ; Biosample/Treatment: tissue, brain/-; Disease: -; SILAC: -;
Curated Info

4

Guo A (2013) CST Curation Set: 18337; Year: ; Biosample/Treatment: tissue, brain/-; Disease: -; SILAC: -;
Curated Info

5

Guo A (2013) CST Curation Set: 18338; Year: ; Biosample/Treatment: tissue, embryo/-; Disease: -; SILAC: -;
Curated Info

6

Guo A (2013) CST Curation Set: 18339; Year: ; Biosample/Treatment: tissue, embryo/-; Disease: -; SILAC: -;
Curated Info

7

Guo A (2013) CST Curation Set: 18340; Year: ; Biosample/Treatment: tissue, embryo/-; Disease: -; SILAC: -;
Curated Info

8

Guo A (2013) CST Curation Set: 18341; Year: ; Biosample/Treatment: tissue, embryo/-; Disease: -; SILAC: -;
Curated Info

9

Guo A (2013) CST Curation Set: 18342; Year: ; Biosample/Treatment: tissue, embryo/-; Disease: -; SILAC: -;
Curated Info

10

Guo A (2013) CST Curation Set: 18343; Year: ; Biosample/Treatment: tissue, embryo/-; Disease: -; SILAC: -;
Curated Info

11

Guo A (2013) CST Curation Set: 18344; Year: ; Biosample/Treatment: tissue, embryo/-; Disease: -; SILAC: -;
Curated Info

12

Guo A (2013) CST Curation Set: 18345; Year: ; Biosample/Treatment: tissue, embryo/-; Disease: -; SILAC: -;
Curated Info

13

Guo A (2013) CST Curation Set: 18346; Year: ; Biosample/Treatment: tissue, embryo/-; Disease: -; SILAC: -;
Curated Info

14

Guo A (2013) CST Curation Set: 18347; Year: ; Biosample/Treatment: tissue, embryo/-; Disease: -; SILAC: -;
Curated Info

15

Guo A (2013) CST Curation Set: 18348; Year: ; Biosample/Treatment: tissue, embryo/-; Disease: -; SILAC: -;
Curated Info

16

Guo A (2013) CST Curation Set: 18349; Year: ; Biosample/Treatment: tissue, embryo/-; Disease: -; SILAC: -;
Curated Info

17

Zhou J (2010) CST Curation Set: 9110; Year: 2010; Biosample/Treatment: cell line, ES J1/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R
Curated Info

18

Zhou J (2010) CST Curation Set: 9114; Year: 2010; Biosample/Treatment: cell line, P19/untreated; Disease: testicular cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R
Curated Info

19

Zhou J (2009) CST Curation Set: 6011; Year: 2012; Biosample/Treatment: cell line, MEF/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R
Curated Info

20

Zhou J (2009) CST Curation Set: 6009; Year: 2012; Biosample/Treatment: cell line, MEF/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R
Curated Info

21

Zhou J (2009) CST Curation Set: 6008; Year: 2012; Biosample/Treatment: cell line, MEF/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R
Curated Info

22

Zhou J (2009) CST Curation Set: 6014; Year: 2012; Biosample/Treatment: cell line, MEF/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R
Curated Info

23

Rikova K (2008) CST Curation Set: 4939; Year: 2008; Biosample/Treatment: cell line, Dana Farber-S1/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R
Curated Info

24

Rikova K (2008) CST Curation Set: 4937; Year: 2008; Biosample/Treatment: cell line, Dana Farber-L1/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R
Curated Info

25

Rikova K (2008) CST Curation Set: 4938; Year: 2008; Biosample/Treatment: cell line, Dana Farber-L2/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R
Curated Info

26

Zhou J (2008) CST Curation Set: 3811; Year: 2008; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R
Curated Info

27

Zhou J (2008) CST Curation Set: 3812; Year: 2008; Biosample/Treatment: tissue, brain, embryonic/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R
Curated Info